<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03457935</url>
  </required_header>
  <id_info>
    <org_study_id>23201</org_study_id>
    <nct_id>NCT03457935</nct_id>
  </id_info>
  <brief_title>Detection of Early Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>The Role of the miR200 Family in the Restoration of Normal Lung Homeostasis and Detection of Early IPF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Temple University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if miR200 family may serve as a biomarker of IPF.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine miR200 levels (fold change) in blood samples.</measure>
    <time_frame>Baseline (one time).</time_frame>
    <description>MicroRNAs (miRs) are noncoding small RNAs, which regulate numerous physiological and pathological processes. miR200 levels will be measured in blood samples collected from control subjects, non-IPF ILD and IPF patients. These samples will be used for identifying biomarkers for IPF.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>No lung diseases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-IPF ILD</arm_group_label>
    <description>non-IPF ILD diagnosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPF</arm_group_label>
    <description>Naive patients with no IPF treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>Blood samples</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Non-IPF ILD</arm_group_label>
    <arm_group_label>IPF</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Controls and subjects with non-IPF ILD and a new diagnosis of IPF.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Control Subjects:

          -  Subjects ≥ 18 y.o.

          -  No lung diseases

        Inclusion Criteria for IPF Patients:

          -  Informed consent

          -  Subjects ≥ 40 y.o.

          -  Naive patients with no IPF treatment

          -  IPF diagnosis based on the ATS/ERS/JRS/ALAT criteria

        Inclusion Criteria for non-IPF ILD Patients:

          -  Informed consent

          -  Subjects ≥ 18 y.o.

          -  ILD diagnosis

        Exclusion Criteria for control subjects, IPF and non-IPF ILD patients:

          -  HIV

          -  Hepatitis B

          -  Hepatitis C

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Beata Kosmider, MS, PhD</last_name>
    <phone>2157079084</phone>
    <email>beata.kosmider@temple.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Kosmider, MS, PhD</last_name>
      <phone>215-707-9084</phone>
      <email>beata.kosmider@temple.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2018</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

